ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2449

Patient-Reported Disease Activity and Outcome In Male Versus Female Patients Of The Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort

Suzanne Arends1,2, Fiona Maas1, Eveline van der Veer3, Reinhard Bos2, Monique Efde2, Martha K. Leijsma1, Hendrika Bootsma1, Elisabeth Brouwer1 and Anneke Spoorenberg1, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, 3Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Disease Activity, patient outcomes, sex bias and spondylarthritis

  • Tweet
  • Email
  • Print
Session Information

Session Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Ankylosing Spondylitis (AS) occurs more often in males than in females. Most women tend to have milder disease and may therefore be underdiagnosed. Male AS patients are more likely to develop radiographic spinal damage. The aim of the present study was to investigate whether there are differences in patient-reported assessments of disease activity, physical function, and quality of life between male and female patients with axial spondyloarthritis (SpA).

Methods: All consecutive patients from the Groningen Leeuwarden Axial SpA (GLAS) cohort who visited the outpatient clinic between January 2011 and December 2012 were included in this cross-sectional analysis. All patients fulfilled the modified New York criteria for AS (>90%) or the ASAS criteria for axial SpA. Disease activity was assessed using Bath AS Disease Activity Index (BASDAI), AS Disease Activity Score (ASDAS; calculated from BASDAI questions 2, 3 and 6, patient global assessment of disease activity (GDA), and, C-reactive protein (CRP)), swollen joint index (range 0-44), and tender joint index (range 0-46). Physical function was assessed using Bath AS Functional Index (BASFI) and quality of life using AS Quality of Life (ASQoL) questionnaire.

Results: Of the 469 included patients, mean age was 45 years (SD±13), mean duration of symptoms was 17 years (range 0-61), 66% were male, and 80% were HLA-B27+. Males were significantly older, had longer disease duration, and were more frequently HLA-B27+ compared to females. Extra-articular manifestations, comorbidity, and current use of NSAID, DMARD, and anti-TNF were comparable between both groups.

Patient-reported measures of disease activity (BASDAI, patient GDA, and tender joints) and outcome (BASFI and ASQoL) were significantly higher in female compared to male patients. ASDAS, capturing both subjective and objective aspects of disease activity, was also significantly higher in females. This difference can be explained by patient-reported aspects of the ASDAS, since CRP levels were comparable between male and female patients (Table 1). Differences remained statistically significant after correcting for age, disease duration, and HLA-B27 status.

Conclusion:  This cross-sectional study shows that patient-reported measures of disease activity and outcome as well as ASDAS were significantly worse in female axial SpA patients. It is important to be aware of these differences when interpreting patient-reported measures in research and clinical practice. These findings underline the importance of research into more balanced and objective markers of disease activity and outcome including biomarkers in axial SpA.

Table 1.Clinical assessments in male and female patients with axial SpA

 

All patients (n=469)

Males (n=310)

Females (n=159)

P-value

BASDAI

3.6 (0.0-9.6)

3.4 (0.0-9.4)

4.2 (0.2-9.6)

0.000

ASDAS(CRP)

2.3 (0.0-5.7)

2.2 (0.0-5.2)

2.5 (0.6-5.7)

0.004

Patient GDA

4 (0-10)

3 (0-10)

5 (0-10)

0.001

CRP (mg/L)

3 (0-94)

3 (0-94)

3 (0-82)

0.415

CRP ≥5

176 (38%)

115 (38%)

61 (39%)

0.731

Swollen joints

0 (0-9)

0 (0-9)

0 (0-2)

0.576

≥1 swollen joint

18 (4%)

13 (4%)

5 (3%)

0.575

Tender joints

0 (0-22)

0 (0-22)

0 (0-19)

0.018

≥1 tender joint

108 (23%)

61 (20%)

47 (30%)

0.020

BASFI

3.3 (0.0-9.9)

3.0 (0.0-9.7)

4.0 (0.0-9.9)

0.030

ASQoL

6 (0-18)

4 (0-18)

7 (0-18)

0.000

Values are presented as median (range) or number of patients (%).


Disclosure:

S. Arends,
None;

F. Maas,
None;

E. van der Veer,
None;

R. Bos,
None;

M. Efde,
None;

M. K. Leijsma,
None;

H. Bootsma,
None;

E. Brouwer,
None;

A. Spoorenberg,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-disease-activity-and-outcome-in-male-versus-female-patients-of-the-groningen-leeuwarden-axial-spondyloarthritis-glas-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies